TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RCC of predominantly clear cell histology~* Either no prior treatment or a maximum of 2 prior treatment regimens for metastatic RCC that included no more than 1 treatment regimen targeting the vascular endothelial growth factor (VEGF) pathway (Phase 1 only)~* At least 1 but no more than 2 prior systemic therapies for metastatic RCC that included no more than 1 therapy targeting the VEGF pathway (Phase 2 only)~* Disease measurable per the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase 2 only)~Exclusion Criteria:~* Presence of acute infection or other significant systemic illness~* Central nervous system involvement by malignancy~* History of other cancer within 5 years~* Previously received rIL-21 or sorafenib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MIHS Emergency Department CPR Quality Improvement Project

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~Exclusion Criteria:~* less than 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Before RTAVF and post-event debriefing (Type: NO_INTERVENTION): Before scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
- After RTAVF and post-event debriefing (Type: ACTIVE_COMPARATOR): After scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent including authorization to release health information~* Moderate (2) or severe (3) glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity (IGA-FWS) scale~* Moderate (2) or severe (3) glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity (PFWS) scale~* Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial~Exclusion Criteria:~* Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis~* Active skin disease, infections or inflammation at the injection sites~* Plan to receive botulinum toxin type A anywhere in the face through the duration of the study~* History of allergy or sensitivity to any botulinum toxin preparations or to any component of the test article~* Current enrollment in an investigational drug or device trial or participation in such a trial within the last 30 days prior to screening through end of trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DaxibotulinumtoxinA 40 units (Type: EXPERIMENTAL): Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
- Placebo (Type: PLACEBO_COMPARATOR): Biological/Vaccine: Placebos Intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV-infection prior to study enrollment~* Screening laboratory result indicating HCV genotype 2 infection~* Subject has plasma HCV ribonucleic acid (RNA) level greater than 10,000 IU/mL at Screening~* Voluntarily sign an informed consent~Exclusion Criteria:~* Co-infection of Hepatitis B Virus (HBV), human immunodeficiency virus (HIV) and any HCV genotype other than genotype 2~* Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir, simeprevir and boceprevir~* Any cause of liver disease other than chronic HCV-infection, including but not limited to the following: hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease; autoimmune hepatitis; alcoholic liver disease; drug-related liver disease~* Clinically significant laboratory abnormalities~* Uncontrolled clinically significant disease, disorder or medical illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 plus RBV for 12 weeks (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
- ABT-450/r/ABT-267 plus RBV for 16 weeks (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities~* Genetically diagnosed Prader-Willi Syndrome~* Received at least one dose of Norditropin® treatment~* Pre-pubertal at start of treatment; assessed by Tanner stage 1, or testicular volume below 4ml (according to Tanner 1976)~Exclusion Criteria:~* Pre-treatment with other Growth Hormone preparation prior to treatment with Norditropin®

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has metastatic or locally advanced solid tumor or multiple myeloma~* Tumor specimen has IGF-1R expression~* Participant agrees to use birth control throughout study~Exclusion Criteria:~* Participant must not be recovering from antineoplastic therapy in the last 4 weeks~* Participant has participated in a clinical trial in the last 4 weeks~* Participant has a history of heart problems such as congestive heart failure, angina, heart attack or stroke in the last 3 months~* Participant is taking growth hormone or growth hormone inhibitors~* If female, participant is pregnant or breastfeeding~* Participant is human immunodeficiency virus (HIV) positive~* Participant has a history of hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) intravenous (IV) infusion 1 time every 1 week (Q1W).
- Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 5 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 10 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 10 mg/kg Q1W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.
- Dalotuzumab 15 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 15 mg/kg Q1W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.
- Dalotuzumab 20 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 20 mg/kg Q1W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.
- Dalotuzumab 20 mg/kg Q2W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion 1 time every 2 weeks (Q2W).
- Dalotuzumab 30 mg/kg Q3W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion1 time every 3 weeks (Q3W).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed 6 months of treatment with the study drug and the Month 6 visit in the core study NCT00537082.~* Females of childbearing potential who have a negative pregnancy test in the core study NCT00537082.~Exclusion Criteria:~* Patients who permanently discontinued study drug treatment prior to the Month 6 visit in the core study NCT00537082.~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod 0.5 mg (Type: EXPERIMENTAL): Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
- Fingolimod 1.25 mg (Type: EXPERIMENTAL): Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
- Placebo-fingolimod (Type: EXPERIMENTAL): Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Corneal Collagen Cross-linking for Progressive Keratoconus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of keratoconus~* Documented progression over previous 24 months~* Decreased BSCVA~* Must complete all study visits~Exclusion Criteria:~* Prior corneal surgery or Intacs~* History of delayed wound healing

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Corneal Collagen Cross-linking (CXL) Treatment Group (Type: ACTIVE_COMPARATOR): riboflavin ophthalmic solution and UVA irradiation
- Control Group (Type: SHAM_COMPARATOR): riboflavin ophthalmic solution without UVA irradiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* newly diagnosed cases histologically as squamous cell carcinoma,~* a performance status 0 to 2,~* white blood cells \>3,000/microL,~* platelets \>100,000/microL,~* serum total bilirubin \<2.0 mg/dl,~* serum transaminase \<3 times the upper normal limit,~* serum creatinine \<1.5 mg/dl,~* creatinine clearance \>60 ml/min~Exclusion Criteria:~* serious cardiac disease~* prior chemotherapy and radiotherapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prediabetic, defined as 2-hour post-load serum glucose between 140 and 199 mg/dl on a 75-gram standard oral glucose tolerance test (OGTT) within the past 90 days~* Family history of type 2 diabetes mellitus~* Body mass index (BMI) between 25 and 35 kg/m2~* English speaker~* Nonsmoker~Exclusion Criteria:~* History of Axis I mood, anxiety, or psychotic disorder, confirmed by Structured Clinical Interview for DSM-IV~* Use of psychotropic drugs

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Aripiprazole (Type: ACTIVE_COMPARATOR): Participants will receive an injection of aripiprazole during the tracer-clamp study.
- Olanzapine (Type: ACTIVE_COMPARATOR): Participants will receive an injection of olanzapine during the tracer-clamp study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Scrambler Therapy or Sham Treatment for Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be 18-50 years of age~* diagnosed with persistent nonspecific LBP~* comprehend English~Exclusion Criteria:~* \<18 or \>50 years of age~* chronic pain at another site or associated with a painful condition~* pregnant or within 3 months post-partum~* implanted drug delivery system~* heart stents or metal implants such as pacemakers, automatic defibrillator, aneurysm clips, vena cave slips, or skull plates~* history of myocardial infarction or ischemic heart disease within the past six months~* history of epilepsy~* skin conditions such as open sores that would prevent proper application of electrodes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Scrambler therapy (Type: EXPERIMENTAL): Scrambler therapy applied to region of low back pain for 30 minutes x 10 days
- Sham Scrambler treatment (Type: SHAM_COMPARATOR): Sham treatment applied to region above low back pain at nontherapeutic dose for 30 minutes x 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Gamified, Social Media Inspired Personalized Normative Feedback Alcohol Intervention for Sexual Minority Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Registered for the online competition~* Accept the competition's Terms of Service \& Privacy Policy~* Endorses a lesbian, bisexual, or queer female sexual identity~* Is between the ages of 21 and 55 years~* Has consumed 3 or more drinks on at least one occasion during the previous 2 months OR consumes alcohol 3 or more days per week~* Lives in North America (US or Canada)~* Does not have a partner or housemate participating~* Accepts invitation and consents to participate in the Evaluation Study~Exclusion Criteria:~* Does not register for the online competition.~* Does not accept the competition's Terms of Service \& Privacy Policy~* Is younger than 21 years of age or older than 55 years of age.~* Has NOT consumed 3 or more drinks on at least one occasion during the previous 2 months AND drinks less than 3 days per week~* Lives outside of North America~* Has a partner or housemate participating~* Declines invitation~* Does not consent to participate in the Evaluation Study

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Alcohol + Stigma Coping PNF (Type: EXPERIMENTAL): Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and two control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on their stigma coping behaviors after answering questions about their stigma coping behaviors and two control topics.
- Alcohol + Control PNF (Type: EXPERIMENTAL): Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on one control topic (Relationships) after answering questions about their stigma coping behaviors and two control topics.
- Control PNF (Type: OTHER): Participants randomized to the control arm will answer questions about the same topics as participants in the other conditions in Round 3 (Alcohol Use \& Control) and Round 4 (Stigma-Coping \& Control). However, in both Rounds 3 and 4 they will receive gamified PNF on control topics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven primary or recurrent, regional melanoma or soft tissue sarcoma that is not amenable to surgical resection~  * Majority (greater than 95%) of disease must be distal to the apex of the femoral triangle in the lower limb and the deltoid insertion in the upper limb~* Bidimensionally measurable disease in the extremity~* Patients with disease beyond the limb are eligible if their extremity disease requires palliative treatment in the judgment of their physician~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* Karnofsky 70-100%~Life expectancy:~* At least 6 months~Hematopoietic:~* WBC at least 3,000/mm\^3~Hepatic:~* Not specified~Renal:~* Creatinine less than 2.0 mg/dL~Cardiovascular:~* Must have palpable femoral/axillary, dorsalis pedis/popliteal, or radial pulses in the extremity to be treated~* No signs or symptoms of vascular insufficiency (no history of claudication or other ischemic peripheral vascular disease)~Other:~* Not pregnant or nursing~* Negative pregnancy test~* No other concurrent serious illness~* No severe diabetes~  * No prior extremity complications due to diabetes~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* At least 4 weeks since prior antitumor therapy and recovered~* At least 2 weeks since prior antibiotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Community Engagement for Early Recognition and Immediate Action in Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 years of age or older~* Hispanic, African American, or Caucasian/White~* Reside within the following Chicago Zip Codes: 60617, 60619, 60620, 60621, 60628, 60629, 06032, 60639, or 60649~Exclusion Criteria:~* \< 18 years old~* Ethnic groups outside our targeted population~* Outside targeted catchment area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Community-based Stroke Awareness Program (Type: None): Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete